The European Center for Disease Prevention and Control said the number of unusual pediatric hepatitis cases reached 450, double the number reported two weeks earlier.
Shares of Madrigal Pharmaceuticals went up in trading after the company announced positive topline data from a Phase III assessment of resmetirom in non-alcoholic fatty liver disease.
Bayer on January 10 struck a partnership deal with Mammoth Biosciences to develop therapeutic tools based on CRISPR/CAS9 gene editing as the German drug maker seeks to widen the company’s cell and gene therapy development efforts.
Merck’s HIV strategy took a major hit as a “very important” aspect, MK-8507, was paused in development after patients experienced a low white blood cell count. East coast neighbor Enanta is also feeling the sting of a failed program with HBV trials, as the Massachusetts biotech is dropping the oral hepatitis B virus RNA destabilizer EDP-721 after healthy participants experienced safety signals.
Gilead Sciences Inc. announced the submission of a Biologics License Application to the U.S. Food and Drug Administration for bulevirtide for injection (2 mg), a potential first-in-class antiviral medicine for the treatment of chronic hepatitis delta virus (HDV) infection in adults with compensated liver disease; bulevirtide has been granted Breakthrough Therapy and Orphan Drug designations by the FDA.
AstraZeneca said on Aug. 26 a late-stage trial showed the company’s medicine for a rare disease that causes accumulation of copper in the body was three times more successful in helping remove deposits from tissues compared with standard care.
International biopharmaceutical firm Genevant Sciences announced a global collaboration and licensing deal with Takeda Pharmaceutical to create and commercialize new therapies that would hopefully treat two undisclosed types of rare liver diseases.
Los Angeles-based biopharmaceutical firm Enochian BioSciences received a green light from the U.S. Food and Drug Administration for feedback on a possible cure for infections caused by the hepatitis B virus (HBV).
Jerusalem-based SpliSense, which focuses on cystic fibrosis and other genetic pulmonary diseases, closed on a $28.5 million Series B financing round. Participating in the round were OrbiMed, Israel Biotech Fund, Integra Holdings and the Cystic Fibrosis Foundation.
SubjectWell – the largest risk-free clinical trials marketplace – released statistics on patients’ attitudes toward clinical research, specifically those with liver diseases.